Effects of County Public Hospital Reform on Procurement Costs and Volume of Antibiotics: A Quasi-Natural Experiment in Hubei Province, China

PharmacoEconomics

Volumn 36, Issue 8, 2018, Pages 995-1004

  Tang, Yuqing ^a   Liu, Chaojie ^b   Liu, Junjie ^a   Zhang, Xinping ^a   Zuo, Keyuan ^c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b LA TROBE UNIVERSITY   (Australia)

^c Hubei Public Resource Trading Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ARTICLE; CHINA; CONTROLLED STUDY; DRUG COST; HEALTH CARE POLICY; INCOME; LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; PUBLIC HOSPITAL; DRUG UTILIZATION; ECONOMICS; HEALTH CARE COST; HUMAN;

ANTI-BACTERIAL AGENTS; CHINA; DRUG UTILIZATION; HEALTH CARE REFORM; HEALTH EXPENDITURES; HOSPITALS, COUNTY; HOSPITALS, PUBLIC; HUMANS;

EID: 85045615660     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-018-0654-1     Document Type: Article

References (52)

1. Huttner A, Albrich WC, Bochud PY, Gayet-Ageron A, Rossel A, Dach EV, et al. PIRATE project: point-of-care, informatics-based randomised controlled trial for decreasing overuse of antibiotic therapy in Gram-negative bacteraemia. BMJ Open. 2017;7(7):e017996.
2. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013;13(12):1057–98.
3. O’Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. 2014. https://www.west-info.eu/. Cited 12 Sept 2017.
4. Goff DA, Kullar R, Goldstein EJC, Gilchrist M, Nathwani D, Cheng AC, et al. A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail. Lancet Infect Dis. 2017;17(2):e56–63.
5. Bogert CAVD, Mestrinaro M, Weerasuriya K. The pursuit of responsible use of medicines: sharing and learning from country experiences. Geneva: World Health Organization; 2012.
6. Heddini A, Cars O, Qiang S, Tomson G. Antibiotic resistance in China—a major future challenge. Lancet. 2009;373(9657):30.
7. Yin X, Song F, Gong Y, Tu X, Wang Y, Cao S, et al. A systematic review of antibiotic utilization in China. J Antimicrob Chemother. 2013;68(11):2445–52.
8. Ren N, Zhou P, Wen X, Li C, Huang X, Guo Y, et al. Point prevalence survey of antimicrobial use in Chinese hospitals in 2012. Am J Infect Control. 2016;44(3):332–9.
9. Mao W, Vu H, Xie Z, Chen W, Tang S. Systematic review on irrational use of medicines in China and Vietnam. PLoS One. 2015;10(3):e0117710.
10. Lin H, Dyar OJ, Rosales-Klintz S, Zhang J, Tomson G, Hao M, et al. Trends and patterns of antibiotic consumption in Shanghai municipality, China: a 6 year surveillance with sales records, 2009-14. J Antimicrob Chemother. 2016;71(6):1723–9.
11. Li J, Song X, Yang T, Chen Y, Gong Y, Yin X, et al. A systematic review of antibiotic prescription associated with upper respiratory tract infections in China. Medicine. 2016;95(19):e3587.
12. Xiao YH, Hou F, Wang J, Yan Q, Sun ZY, Lv XJ. An investigation into socio-economic impact of adverse drug reactions of antibacterial agent irrational use. Chin Health Econ. 2010;29:94–9.
13. Yip WC, Hsiao WC, Chen W, Hu S, Ma J, Maynard A. Early appraisal of China’s huge and complex health-care reforms. Lancet (London, England). 2012;379(9818):833–42.
14. Hu S, Tang S, Liu Y, Zhao Y, Escobar ML, de Ferranti D. Reform of how health care is paid for in China: challenges and opportunities. Lancet (London, England). 2008;372(9652):1846–53.
15. Ran LM, Luo KJ, Wu YC, Yao L, Feng YM. An analysis of China’s physician salary payment system. J Huazhong Univ Sci Technol Med Sci. 2013;33(2):309–14.
16. Yip W, Hsiao WC. The Chinese health system at a crossroads. Health Affairs (Project Hope). 2008;27(2):460–8.
17. Tang Y, Liu C, Zhang X. Delivery of essential medicines to primary care institutions and its association with procurement volume and price: a case study in Hubei Province, China. Appl Health Econ Health Policy. 2017;15(1):57–64.
18. Yang W. How does the pharmaceutical industry influence prescription? A qualitative study of provider payment incentives and drug remunerations in hospitals in Shanghai. Health Econ Policy Law. 2016;11(4):379–95.
19. Currie J, Lin W, Zhang W. Patient knowledge and antibiotic abuse: evidence from an audit study in China. J Health Econ. 2011;30(5):933–49.
20. Currie J, Lin W, Meng J. Addressing antibiotic abuse in China: an experimental audit study. J Dev Econ. 2014;01(110):39–51.
21. Hu J, Mossialos E. Pharmaceutical pricing and reimbursement in China: when the whole is less than the sum of its parts. Health Policy (Amsterdam, Netherlands). 2016;120(5):519–34.
22. Liang H, Ding J, Xue Y. China’s drug innovation and policy environment. Drug Discov Today. 2011;16(1–2):1–3.
23. Reynolds L, McKee M. Factors influencing antibiotic prescribing in China: an exploratory analysis. Health Policy (Amsterdam, Netherlands). 2009;90(1):32–6.
24. Zhang W, Liu X, Wang Y, Chen Y, Huang M, Fan M, et al. Antibiotic use in pulmonology wards of Chinese children’s hospitals: 2002–2006. J Clin Pharm Ther. 2009;34(1):61–5.
25. Meng Q, Cheng G, Silver L, Sun X, Rehnberg C, Tomson G. The impact of China’s retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals. Health Policy Plan. 2005;20(3):185–96.
26. Han S, Liang H, Su W, Xue Y, Shi L. Can price controls reduce pharmaceutical expenses? A case study of antibacterial expenditures in 12 Chinese hospitals from 1996 to 2005. Int J Health Serv. 2013;43(1):91–103.
27. Li Y, Xu J, Wang F, Wang B, Liu L, Hou W, et al. Overprescribing in China, driven by financial incentives, results in very high use of antibiotics, injections, and corticosteroids. Health Affairs (Project Hope). 2012;31(5):1075–82.
28. Guan X, Liang H, Xue Y, Shi L. An analysis of China’s national essential medicines policy. J Public Health Policy. 2011;32(3):305–19.
29. Tang Y, Zhang X, Yang C, Yang L, Wang H, Zhang X. Application of propensity scores to estimate the association between government subsidy and injection use in primary health care institutions in China. BMC Health Serv Res. 2013;21(13):183.
30. Chen M, Wang L, Chen W, Zhang L, Jiang H, Mao W. Does economic incentive matter for rational use of medicine? China’s experience from the essential medicines program. PharmacoEconomics. 2014;32(3):245–55.
31. Yang L, Liu C, Ferrier JA, Zhou W, Zhang X. The impact of the National Essential Medicines Policy on prescribing behaviours in primary care facilities in Hubei province of China. Health Policy Plan. 2013;28(7):750–60.
32. Yi H, Miller G, Zhang L, Li S, Rozelle S. Intended and unintended consequences of China’s zero markup drug policy. Health Affairs (Project Hope). 2015;34(8):1391–8.
33. Zhang S, Zhang W, Zhou H, Xu H, Qu Z, Guo M, et al. How China’s new health reform influences village doctors’ income structure: evidence from a qualitative study in six counties in China. Hum Resour Health. 2015;05(13):26.
34. CfHSa Information. An analysis report of National Health Services Survey in China. Beijing: Center for Health Statistics and Information; 2009.
35. National Health and Family Planning Commission of China. Statistical bulletin of China’s health service development of 2010. http://www.moh.gov.cn. Cited 1 Aug 2017.
36. Zhang H, Hu H, Wu C, Yu H, Dong H. Impact of China’s public hospital reform on healthcare expenditures and utilization: a case study in ZJ Province. PLoS One. 2015;10(11):e0143130.
37. Zhang Y, Ma Q, Chen Y, Gao H. Effects of public hospital reform on inpatient expenditures in rural China. Health Econ. 2017;26(4):421–30.
38. Bureau of Statistics of Hubei Province. Hubei statistic year book 2015; 2015. http://www.stats-hb.gov.cn/info/iIndex.jsp?cat_id=10055. Cited 31 Dec 2015.
39. National Health and Family Planning Commission of China. China Health Statistics Yearbook; 2015. http://www.nhfpc.gov.cn/zwgkzt/pwstj/list.shtml. Cited 1 May 2017.
40. Government of Hubei Province. Guidelines for price adjustment of medical services in county-level public hospitals comprehensive reform pilot hospitals in Hubei province. 2014. http://www.macheng.gov.cn/info/1440/14215.htm. Cited 15 Sept 2017.
41. Andersson K, Petzold MG, Sonesson C, Lonnroth K, Carlsten A. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986–2002. Health Policy (Amsterdam, Netherlands). 2006;79(2–3):231–43.
42. Benjamini Y, Hochberg Y. Controlling the false discovery rate—a practical and powerful approach to multiple testing. J R Stat Soc. 1995;57(1):289–300.
43. Angrist JD, Krueger AB. Empirical strategies in labor economics. Soc Sci Electron Publ. 2006;3(1):1277–366.
44. Duflo E, Mullainathan S, Bertrand M. How much should we trust difference-in-difference estimates. Q J Econ. 2004;119(1):249–75.
45. Zhao D, Zhang Z. Qualitative analysis of direction of public hospital reforms in China. Front Med. 2017. 10.1007/s11684-017-0534-7.
46. Health Mo. China’s health statistics yearbook 2012. Beijing: China Statistics Press; 2013.
47. Reynolds L, McKee M. Serve the people or close the sale? Profit-driven overuse of injections and infusions in China’s market-based healthcare system. Int J Health Plan Manag. 2011;26(4):449–70.
48. Ding L, Sun Q, Sun W, Du Y, Li Y, Bian X, et al. Antibiotic use in rural China: a cross-sectional survey of knowledge, attitudes and self-reported practices among caregivers in Shandong province. BMC Infect Dis. 2015;21(15):576.
49. Sun Q, Dyar OJ, Zhao L, Tomson G, Nilsson LE, Grape M, et al. Overuse of antibiotics for the common cold—attitudes and behaviors among doctors in rural areas of Shandong Province, China. BMC Pharmacol Toxicol. 2015;31(16):6.
50. Fu H, Li L, Li M, Yang C, Hsiao W. An evaluation of systemic reforms of public hospitals: the Sanming model in China. Health Policy Plan. 2017;32(8):1135–45.
51. Li L, Fu H. China’s health care system reform: progress and prospects. Int J Health Plan Manag. 2017;32(3):240–53.
52. Si L, Chen M, Palmer AJ. Has equity in government subsidy on healthcare improved in China? Evidence from the China’s National Health Services Survey. Int J Equity Health. 2017;16(1):6.